Coronavirus (COVID-19)

We’re supporting the NHS and social care by providing guidance about COVID-19 and backing efforts to get promising diagnostics and treatments to patients quickly. We update our guidance when new evidence comes out so that the health and care system can find current, reliable advice as it continues to respond to the pandemic.

Having prioritised therapeutically critical topics earlier in the pandemic, we’ve begun to publish planned guidance again now that the health and care system is starting to return to normal arrangements.

Everything we've said relevant to COVID-19Register for updates

More information

Developing rapid guidelines

Rapid guidelines are developed with NHS England and NHS Improvement and a cross-speciality clinical group, supported by the specialist societies and royal colleges. They are developed quickly using a different approach to normal. We’re keeping them under review.

More information about other topics we're looking at and how they are prioritised is available.

Developing rapid evidence summaries

These look at whether certain medicines may increase the severity or length of COVID-19 illness. 

We're working with the Medicines and Healthcare products Regulatory Agency. Together we'll facilitate rapid review of information and advice on the safety and efficacy of treatments for COVID-19.

Evidence standards framework for COVID-19 diagnostic tests

This framework helps manufacturers gather the best possible data and evidence. Making sure developers are working to the same standards supports investment into good quality trials and studies. It could also speed up the availability of accurate tests for use in the NHS.

Guide to evidence collection for COVID-19 medicines

You can read our guide, developed with the NIHR, on clinical evidence generation for COVID-19 medicines. We can also provide free scientific advice for researchers developing novel diagnostics or therapeutics for COVID-19.

Using wider sources of data and evidence in our COVID-19 work

We've developed a guide on assessing the quality of wider sources of data and evidence in our COVID-19 guidance. It's for internal guidance developers and external collaborators.

Reuse or reproduction outside the UK

For our COVID-19 products we have waived our normal licensing requirements for international reuse or reproduction of our content.

Tell us what you think

Email us with any feedback about our rapid guidelines and evidence summaries.